Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti
tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung
cancer participants.